



Receptor Logic Quarterly Update
Business News - Winter 2008

Receptor Logic Lab Relocates to Abilene

Receptor Logic has moved the company's laboratory from Amarillo to Abilene. For the next year, Receptor Logic will lease approximately 3,000 square feet of lab space in the new Texas Tech University Health Sciences Center School of Pharmacy building in north Abilene, making Abilene home to its first biotechnology company.

\$2 Million Location Incentive Award

In addition to the \$2 million in private funds raised by Emergent Technologies, Inc., the Development Corporation of Abilene (DCOA) has pledged up to \$2 million to assist Receptor Logic. The DCOA funding largely will cover the cost of new lab equipment. The DCOA eventually will provide a space for the Receptor Logic to occupy permanently.

By 2013, Receptor Logic plans to employ 40 scientists and technicians with an average salary of \$50,000 to \$60,000. Over five years, its payroll will increase from \$300,000 to \$2.8 million.

.....
**Dr. Jon Weidanz Appointed Director of New
Center for Immunotherapeutic Research**

Dr. Weidanz, Founder and Chief Scientist of Receptor Logic and Associate Professor at the TTUHSC School of Pharmacy in Abilene, will be the director of the new Center for Immunotherapeutic Research. The Center for Immunotherapeutic Research will employ top scientists and attract biotech companies to Abilene. The Center, which will receive startup funds from the Development Corporation of Abilene (DCOA), will be based at the Abilene branch of the TTUHSC School of Pharmacy, 1718 Pine St.

The program initially will be funded by \$3 million from the DCOA and \$4.5 million from the TTUHSC. After five years, leaders hope the program will begin to sustain itself through research grants and other sources of revenue. It is proposed that after five years, the Center will employ seven faculty members (including Dr. Weidanz as Director) and six graduate students, post-doctoral fellows or staff members.

The DCOA and TTUHSC funding may leverage state grant money that pays for recruiting talented individuals from outside Texas.

Continued on page 2.



Page 2 of 4

Receptor Logic Quarterly Update
Business News – Winter 2008

Dr. Weidanz Appointed Director of New Center for Immunotherapeutic Research Center, cont.

Beyond the job growth in the pharmacy school's immunotherapeutic research center, there is great potential for growth in the private sector. The goal of the center is to attract world-class scientists like Dr. Weidanz who are interested in commercializing their research. Dr. Weidanz' company, Receptor Logic, will act as a foundation to attract similar companies. Dr. Weidanz is already in talks with three top scientists from outside Texas who are interested in the business commercialization aspect of their research.

New start-up companies will fill space in the high-tech lab building recently approved by the DCOA board. The building, called an Accelerator, will provide 23,000 square-feet of lab space and state-of-the-art equipment for up to six startup companies.

"We've accomplished in months what normally takes years, and that's because everybody can see the benefits," says Richard Burdine, Chief Executive Officer of the DCOA.

- DCOA assistance after five years: \$3 million
- Laboratory startup packages for five faculty members, \$1.2 million
- Communication equipment: \$30,000
- Lab equipment and research infrastructure: \$500,000
- Research grants (15 percent match): \$600,000
- Pharmacy practice research: \$270,000
- Additional capital equipment: \$400,000

Source: Development Corporation of Abilene

Continued on page 3.



Center for Immunotherapeutic Research Program

Five faculty members with an interest in immunology will work together to research and develop biotechnology. The Center is unique in that it pairs scientists with faculty members who specialize in practicing pharmacy. The Center will focus on commercializing technology that is developed in labs. The Center's goal is to attract researchers who have started their own companies or who have received grants to fund their work.

Receptor Logic Hires New Director of Sales

Receptor Logic is pleased to announce that Chris Johnson has joined the Receptor Logic team as Director of Sales. In this new position Chris will help lead Receptor Logic's growth initiatives.

Chris' sales background extends from product concept and establishing co-development relationships with early adopters to product launch and sales maintenance. He has 10 years experience in the life sciences industry, including positions with Luminex Corporation and PerkinElmer. Chris' has a successful sales track record with expertise in molecular reagents and molecular medicine instrumentation. He holds a Bachelor of Science degree in Microbiology from Texas Tech University.

Dr. Weidanz Receives Prestigious Texas Tech Awards

Dr. Jon Weidanz was recently honored with the Texas Tech University Chancellor's Council Distinguished Teaching and Research Award. This is the seventh year that the Council has recognized the distinguished work of TTU faculty with these awards.

In October 2007 Dr. Weidanz was presented the 2007 TTU President's Excellence in Teaching Award for his sustained excellence in teaching and his strong commitment to the educational process at the Texas Tech University Health Sciences Center.

In the past Dr. Weidanz has received the TTU School of Pharmacy Teacher of the Year Award four times for his exceptional efforts on behalf of the university's School of Pharmacy.

Continued on page 4.



Page 4 of 4

Receptor Logic Featured in *Genetic Engineering News*

The September 15, 2007 edition of *Genetic Engineering News* included a cover story, "Ways to Arm Antibodies Under Increasing Scrutiny – Researchers Are Reviving the Concept of Immunoconjugate Antibodies." Receptor Logic was featured prominently in the article and a Receptor Logic chart was used on the cover page of the publication.

This article represents excellent national exposure for Receptor Logic. *Genetic Engineering News* is one of the top U.S. trade publications in the life sciences industry and has a circulation of more than 76,000.

Receptor Logic at the 13th Annual Conference on Human Antibodies and Hybridomas HAH 2007 - Milan, Italy

At the preeminent international conference, HAH 2007, held in Milan, Italy, October 29-31, 2007, Dr. Weidanz was a U.S. delegate and a presenter at the conference. In the six conference session tracks, Dr. Weidanz was a presenter in the Cancer Session and gave a well-received presentation on the topic, "Monoclonal Antibodies that mimic the T cell receptor and human disease."

The HAH 2007 conference was attended by scientists from around the globe and there were conference attendees from 27 countries.
